Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT00519532




Registration number
NCT00519532
Ethics application status
Date submitted
21/08/2007
Date registered
22/08/2007
Date last updated
27/10/2014

Titles & IDs
Public title
Long-term Extension of RECOVER- Long-term Effect of the 24h Transdermal Delivery of Rotigotine in Subjects With Idiopathic Parkinson's Disease
Scientific title
A Multicenter, Multinational, Phase 3b, Open-label Extension Trial to Evaluate the Long-term Effect of the 24-hour Transdermal Delivery of Rotigotine on Motor Function, Sleep Quality, and Nocturnal and Non-motor Symptoms in Subjects With Idiopathic Parkinson's Disease
Secondary ID [1] 0 0
EudraCT number: 2006-006907-35
Secondary ID [2] 0 0
SP0915
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Parkinson's Disease 0 0
Condition category
Condition code
Neurological 0 0 0 0
Parkinson's disease

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Rotigotine

Experimental: Rotigotine - Rotigotine Transdermal Patch


Treatment: Drugs: Rotigotine
Rotigotine transdermal patches:
10cm2 (2mg/24h); 20cm2 (4mg/24h); 30cm2 (6mg/24h); 40cm2 (8mg/24h)
Optimal dosing: The maximum rotigotine dose allowed is 16mg/24h
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Change From Baseline in UPDRS III Score at Week 13 (End of Maintenance)
Timepoint [1] 0 0
Baseline (baseline SP915) and week 13 (End of maintenance)
Primary outcome [2] 0 0
Change From Baseline in Parkinson Disease Sleep Scale (PDSS) at Week 13 (End of Maintenance)
Timepoint [2] 0 0
Baseline (baseline SP889 NCT00474058) and week 13 (End of maintenance)
Secondary outcome [1] 0 0
Change From Baseline in Nocturnal Akinesia, Dystonia, and Cramps Score (NADCS) at Week 13 (End of Maintenance)
Timepoint [1] 0 0
Baseline (baseline SP889 NCT00474058) and week 13 (End of maintenance)
Secondary outcome [2] 0 0
Change From Baseline in Number of Nocturias at Week 13 (End of Maintenance)
Timepoint [2] 0 0
Baseline (baseline SP889 NCT00474058) and week 13 (End of maintenance)

Eligibility
Key inclusion criteria
- Completion of trial SP889
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Ongoing serious adverse event assessed as related to trial medication

Study design
Purpose of the study
Treatment
Allocation to intervention
N/A
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Terminated
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/07/2007
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/05/2009
Sample size
Target
Accrual to date
Final
84
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
- Concord
Recruitment postcode(s) [1] 0 0
- Concord
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Florida
Country [2] 0 0
United States of America
State/province [2] 0 0
North Carolina
Country [3] 0 0
Finland
State/province [3] 0 0
Oulu
Country [4] 0 0
Germany
State/province [4] 0 0
Berlin
Country [5] 0 0
Germany
State/province [5] 0 0
Dresden
Country [6] 0 0
Germany
State/province [6] 0 0
Kassel
Country [7] 0 0
Germany
State/province [7] 0 0
Marburg
Country [8] 0 0
Germany
State/province [8] 0 0
Naumburg
Country [9] 0 0
Germany
State/province [9] 0 0
Ulm
Country [10] 0 0
Hungary
State/province [10] 0 0
Budapest
Country [11] 0 0
Hungary
State/province [11] 0 0
Nyiregyhaza
Country [12] 0 0
Italy
State/province [12] 0 0
Chieti
Country [13] 0 0
Italy
State/province [13] 0 0
Milano
Country [14] 0 0
New Zealand
State/province [14] 0 0
Christchurch
Country [15] 0 0
Poland
State/province [15] 0 0
Olyszytn
Country [16] 0 0
South Africa
State/province [16] 0 0
Cape Town
Country [17] 0 0
Spain
State/province [17] 0 0
Barcelona
Country [18] 0 0
Spain
State/province [18] 0 0
Madrid
Country [19] 0 0
United Kingdom
State/province [19] 0 0
Lancashire
Country [20] 0 0
United Kingdom
State/province [20] 0 0
Liverpool

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
UCB Pharma
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The objective of this open-label extension is to assess the long-term effect of the 24-hour
transdermal delivery of rotigotine on motor function, sleep quality, and nocturnal and
non-motor symptoms of Parkinson's disease. The long-term safety and tolerability of the
rotigotine transdermal patch will also be evaluated.
Trial website
https://clinicaltrials.gov/ct2/show/NCT00519532
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
UCB Clinical Trial Call Center
Address 0 0
+1 877 822 9493 (UCB)
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT00519532